The PHI, approved by the U.S. FDA in 2012, integrates total PSA, free PSA, and [−2]proPSA into a single composite score and outperforms individual measurements for clinically significant PCa [371]. This evidence concerns the gene KLK3 and posterior cortical atrophy.